Motor effects induced by a blockade of adenosine A(2A) receptors in the caudate-putamen

NeuroReport

Volumn 9, Issue 8, 1998, Pages 1803-1806

  Hauber, W ^a   Nagel, J ^a   Sauer, R ^b   Muller C E ^b  

^a UNIVERSITY OF STUTTGART   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adenosine A(2A) receptors; Catalepsy; Caudate putamen; Dopamine D( 1 4 ) receptors; MSX 3; Raclopride; Rat; SCH23390; Sniffing

Indexed keywords

3 (3 HYDROXYPROPYL) 8 (METHOXYSTYRYL) 7 METHYL 1 PROPARGYLXANTHINE; 3 (3 HYDROXYPROPYL) 8 (METHOXYSTYRYL) 7 METHYL 1 PROPARGYLXANTHINE PHOSPHATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; DISODIUM HYDROGEN PHOSPHATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MSX 2; MSX 3; PRODRUG; RACLOPRIDE TARTRATE; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CAUDATE NUCLEUS; CONTROLLED STUDY; DOSE RESPONSE; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RAT; SNIFFING;

EID: 0032102161     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199806010-00024     Document Type: Article

References (22)

1. Müller CE and Stein B. Curr Pharm Design 2, 501-530 (1996).
2. Latini S, Pazzagli M, Pepeu G et al. Gen Pharmacol 27, 925-933 (1996).
3. Schiffmann SN, Jacobs O and Vanderhaeghen JJ. J Neurochem 57, 1062-1067 (1991).
4. Ferré S, Fredholm BB, Morelli M et al. Trends Neurosci 20, 452-487 (1997).
5. Kanda T, Shiozaki S, Shimada J et al. Eur J Pharmacol 256, 263-268 (1994).
6. Jiang H, Jacksonlewis V, Muthane U et al. Brain Res 613, 347-351 (1993).
7. Pinna A, Di Chiara G, Wardas J et al. Eur J Neurosci 8, 1176-1181 (1996).
8. Müller CE, Sauer R, Maurish Y et al. Drug Dev Res in press (1998).
9. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press, 1986.
10. Schmidt WJ. Psychopharmacology 90, 123-130 (1986).
11. Anderson JJ, Randall S and Chase TN. J Pharmacol Exp Ther 274, 928-936 (1995).
12. Sarges R, Howard HR, Browne RG et al. J Med Chem 33, 2240-2254 (1990)
13. Vellucci SV, Sirinathsinghji DJS and Richardson PJ. Psychopharmacology 111, 383-388 (1993).
14. Kelley AE, Lang CG and Gauthier AM. Psychopharmacology 95, 556-659 (1988).
15. Kelley AE and Delfs JM. Neuroscience 60, 85-95 (1994).
16. Avdelidis D and Spyraki C. Brain Res Bull 16, 25-32 (1986).
17. Ongini E and Fredholm BB. Trends Pharmacol Sci 17, 364-372 (1996).
18. Huston JP, Haas HL, Boix F et al. Neuroscience 73, 99-107 (1996).
19. Jacobson KA, Nikodijevic O, Padgett WL et al. FEBS Lett 323, 141-144 (1993).
20. Sakata T and Fuchimoto H. Jpn J Pharmacol 23, 781-785 (1973).
21. Ögren SO and Fuxe K. Neurosci Lett 85, 333-338 (1988).
22. Richardson PJ, Kase H and Jenner P. Trends Pharmacol Sci 18, 338-344 (1997).